1. Home
  2. MRKR vs GIFT Comparison

MRKR vs GIFT Comparison

Compare MRKR & GIFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

BUY

Current Price

$0.95

Market Cap

19.5M

Sector

Health Care

ML Signal

BUY

Logo RDE Inc.

GIFT

RDE Inc.

N/A

Current Price

$0.58

Market Cap

22.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
MRKR
GIFT
Founded
1999
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Catalog/Specialty Distribution
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
19.5M
22.0M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
MRKR
GIFT
Price
$0.95
$0.58
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $7.87
N/A
AVG Volume (30 Days)
60.0K
★ 69.9K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
33.61
★ 52.05
EPS
N/A
★ N/A
Revenue
N/A
★ $83,181,716.00
Revenue This Year
$19.61
$6.02
Revenue Next Year
$375.85
$8.42
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.84
$0.44
52 Week High
$2.46
$1.29

Technical Indicators

Market Signals
Indicator
MRKR
GIFT
Relative Strength Index (RSI) 31.50 40.12
Support Level N/A $0.44
Resistance Level $1.31 $1.07
Average True Range (ATR) 0.07 0.10
MACD -0.02 0.00
Stochastic Oscillator 5.58 43.13

Price Performance

Historical Comparison
MRKR
GIFT

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

About GIFT RDE Inc.

Giftify Inc operates in the incentive and rewards industry with a focus on retail, dining, and entertainment experiences, as the owner and operator of digital platforms, CardCash.com, Restaurant.com, and Takeout7.com. CardCash.com is a secondary gift card exchange platform, allowing consumers and retailers to buy and sell gift cards at various scales from several retailers; Restaurant.com is a restaurant-focused digital deals brand, connecting digital consumers and businesses by offering dining, retail, and entertainment deal options at several restaurants and retailers; and Takeout7 is a restaurant technology company offering online ordering solutions and AI-powered digital marketing services. Giftify has one segment, the sale of gift cards and discount certificates to its customers.

Share on Social Networks: